Sukanya Raghavan
Overview
Explore the profile of Sukanya Raghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eklund E, Svensson J, Naslund L, Yhr M, Sayin S, Wiel C, et al.
J Exp Clin Cancer Res
. 2025 Feb;
44(1):75.
PMID: 40011914
Background: In non-small cell lung cancer (NSCLC), the rapid advancement of predictive genetic testing of tumors by identifying specific pathogenic driver variants has significantly improved treatment guidance. However, immune checkpoint...
2.
Sundstrom P, Dutta N, Rodin W, Hallqvist A, Raghavan S, Quiding Jarbrink M
Oncoimmunology
. 2024 Feb;
13(1):2312631.
PMID: 38343750
Mucosal-associated invariant T (MAIT) cells constitute one of the most numerous unconventional T cell subsets, and are characterized by rapid release of Th1- and Th17-associated cytokines and increased cytotoxic functions...
3.
Dutta N, Rohlin A, Eklund E, Magnusson M, Nilsson F, Akyurek L, et al.
Front Oncol
. 2023 Feb;
12:1073457.
PMID: 36844924
Objectives: Immunotherapy by blocking programmed death protein-1 (PD-1) or programmed death protein-ligand1 (PD-L1) with antibodies (PD-1 blockade) has revolutionized treatment options for patients with non-small cell lung cancer (NSCLC). However,...
4.
Eklund E, Wiel C, Fagman H, Akyurek L, Raghavan S, Nyman J, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565194
There is an urgent need to identify new predictive biomarkers for treatment response to both platinum doublet chemotherapy (PT) and immune checkpoint blockade (ICB). Here, we evaluated whether treatment outcome...
5.
Raghavan S, Tovbis-Shifrin N, Kochel C, Sawant A, Mello M, Sathe M, et al.
Front Immunol
. 2021 Dec;
12:752348.
PMID: 34912335
Programmed cell death-1 (PD-1) blockade has a profound effect on the ability of the immune system to eliminate tumors, but many questions remain about the cell types involved and the...
6.
Hallqvist A, Rohlin A, Raghavan S
Scand J Immunol
. 2020 Oct;
92(6):e12980.
PMID: 33015859
Immunotherapy with PD-1 and PD-L1 inhibitors has revolutionized the treatment for patients with NSCLC the last years with increased overall survival and in particular increased number of long-time survivors in...
7.
Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APC mice
Szeponik L, Akeus P, Rodin W, Raghavan S, Quiding-Jarbrink M
Cancer Immunol Immunother
. 2020 Mar;
69(7):1279-1292.
PMID: 32185408
The presence of activated T cells in colorectal cancer tissues is a strong predictor of patient survival. Our previous studies have shown that regulatory T cells (Treg) are able to...
8.
Longet S, Abautret-Daly A, Davitt C, McEntee C, Aversa V, Rosa M, et al.
NPJ Vaccines
. 2019 Nov;
4:45.
PMID: 31666991
causes chronic gastric infection that can lead to peptic ulcers and is an identified risk factor for gastric cancer development. Although much effort has been put into the development of...
9.
Akter S, Jeverstam F, Lundgren A, Magnusson M, Walduck A, Qadri F, et al.
Helicobacter
. 2019 Sep;
24(6):e12658.
PMID: 31502365
Background: Chronic Helicobacter pylori infection is the cause of peptic ulcers in a subpopulation of individuals and a risk factor for the development of gastric cancer. A vaccine against H ...
10.
Walduck A, Raghavan S
Adv Exp Med Biol
. 2019 Apr;
1149:257-275.
PMID: 31016627
Helicobacter pylori is a highly-adapted gastrointestinal pathogen of humans and the immunology of this chronic infection is extremely complex. Despite the availability of antibiotic therapy, the global incidence of H....